GLP-1 and dual GIP/GLP-1 receptor agonists' psychopharmacology and putative neuropsychiatric associated effects: a Bradford Hill-informed, systematic, evaluation.
Current evidence suggests a potential link between GLP-1 receptor agonists and neuropsychiatric disorders, but causality has not been established.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
This review evaluates the evidence linking GLP-1 and GIP/GLP-1 receptor agonists to neuropsychiatric outcomes. It integrates data from various studies to assess potential associations with conditions such as depression and anxiety. The findings indicate biological plausibility but insufficient evidence to establish causality.
Abstract
<h4>Purpose of review</h4>This review evaluates evidence linking both GLP-1 and GIP/GLP-1RAs' exposure to a range of neuropsychiatric outcomes using the Bradford Hill criteria for causal inference.<h4>Recent findings</h4>Glucagon-like peptide-1 (GLP-1) and the dual glucose-dependent insulinotropic polypeptide-GIP/GLP-1 receptor agonists (RAs) are incretin-based medications widely prescribed for type 2 diabetes mellitus and obesity, with demonstrated cardiometabolic benefit and rapidly expanding population exposure. In parallel, post-marketing surveillance and emerging translational research have raised questions regarding potential central nervous system effects, including neuropsychiatric adverse events and psychopharmacological properties. Integrating data from receptor pharmacology, preclinical neuroscience, randomized controlled trials, and observational and pharmacovigilance studies, the strength, consistency, biological plausibility, and experimental support for reported associations with depression, anxiety, suicidality, reward-related behaviour, cognitive effects and retinal/ocular related disturbances were here assessed. Implications for clinical risk-benefit assessment were discussed as well. Current evidence supports potential biological plausibility of a relationship between GLP-1 RAs and a range of psychopathological disorders but remains insufficient to establish causality for most neuropsychiatric outcomes, suggesting the need for prospective, mechanism-informed clinical studies.
Background
This review addresses the potential neuropsychiatric effects of GLP-1 and GIP/GLP-1 receptor agonists, which are commonly used in treating type 2 diabetes and obesity. Prior studies have indicated cardiometabolic benefits, but emerging concerns about neuropsychiatric adverse events necessitate a thorough evaluation. Understanding these associations is crucial for assessing the overall risk-benefit profile of these medications.
Methods
The review integrates data from receptor pharmacology, preclinical neuroscience, randomized controlled trials, observational studies, and pharmacovigilance reports. It employs the Bradford Hill criteria for causal inference to evaluate the strength and consistency of the evidence. Specific details on population size, dose, duration, and outcome measures are not reported in abstract.
Results
The review indicates potential associations between GLP-1 receptor agonists and neuropsychiatric outcomes such as depression and anxiety. However, it emphasizes that the evidence is insufficient to establish causality for most outcomes assessed. Specific numeric findings or statistical analyses are not reported in abstract.
Interpretation
The findings suggest a biologically plausible link between GLP-1 receptor agonists and neuropsychiatric disorders, aligning with some preclinical and observational studies. However, the lack of definitive causal evidence limits the clinical implications of these associations. The review underscores the need for more rigorous, prospective studies to clarify these relationships.
Key findings
- Current evidence supports potential biological plausibility of a relationship between GLP-1 RAs and a range of psychopathological disorders.
- Insufficient evidence to establish causality for most neuropsychiatric outcomes.
- Emerging translational research has raised questions regarding potential central nervous system effects.
Limitations
- Insufficient evidence to establish causality for most neuropsychiatric outcomes.
- Integration of various study types may introduce confounding factors.
- No specific numeric findings or statistical analyses reported.